The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

About 3.5 million persons used PrEP in 2023 globally, which was far below the goal of 21.2 million set for 2025 ...

(HealthDay News) — Discontinuing cholinesterase inhibitors upon memantine initiation is not associated with an increased risk for long-term care institutionalization among older adults with dementia, ...

Tumor HI is a rare condition that results in hypoglycemia caused by either islet cell tumors (eg, insulinomas) or non-islet cell tumors (eg, hepatocellular carcinoma).

Most common exclusion criteria were major depressive disorder, malignant neoplasms, liver disease, uncontrolled HTN ...

Three good practice statements include regularly testing serum iron studies, which can influence decision to use oral or IV iron treatment ...

The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Applied Therapeutics regarding the New Drug Application (NDA) for govorestat for the treatment of classic ...

The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...

The health system defended itself by claiming it had done nothing wrong, and that Dr T had a clear duty to inform it of the ...

According to the Company, the premixed bags were developed to reduce preparation time and the risk of preparation errors.

Skysona is indicated to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy.

More than 7 million Americans struggling with obesity would become eligible for coverage under the proposed change ...